Arcturus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Arcturus Therapeutics Holdings
ARCT Stock  USD 18.05  0.00  0.00%   
Arcturus Therapeutics financial statements provide useful quarterly and yearly information to potential Arcturus Therapeutics Holdings investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Arcturus Therapeutics financial statements helps investors assess Arcturus Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Arcturus Therapeutics' valuation are summarized below:
Gross Profit
-27.6 M
Profit Margin
(0.39)
Market Capitalization
488.9 M
Enterprise Value Revenue
1.9736
Revenue
160.4 M
There are currently one hundred twenty fundamental signals for Arcturus Therapeutics Holdings that can be evaluated and compared over time across rivals. All traders should validate Arcturus Therapeutics' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 72.5 M in 2025. Enterprise Value is likely to drop to about 86.5 M in 2025

Arcturus Therapeutics Total Revenue

190.48 Million

Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 530 K or Selling General Administrative of 63.8 M, as well as many indicators such as Price To Sales Ratio of 4.55, Dividend Yield of 0.0 or PTB Ratio of 2.85. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Arcturus Therapeutics Correlation against competitors.

Arcturus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets518.5 M493.8 M196.1 M
Slightly volatile
Total Current Liabilities99 M94.3 M38 M
Slightly volatile
Property Plant And Equipment Net49.4 M47.1 M13.3 M
Slightly volatile
Accounts Payable3.8 M6.1 M3.4 M
Slightly volatile
Cash352.6 M335.8 M148.9 M
Slightly volatile
Non Current Assets Total51.7 M49.2 M15.4 M
Slightly volatile
Non Currrent Assets Other2.3 M2.2 M637.9 K
Slightly volatile
Cash And Short Term Investments352.6 M335.8 M158.5 M
Slightly volatile
Net Receivables38.7 M36.9 M7.8 M
Slightly volatile
Common Stock Total Equity28.4 K29.9 K52.6 K
Very volatile
Common Stock Shares Outstanding32.2 M30.6 M12.7 M
Slightly volatile
Liabilities And Stockholders Equity518.5 M493.8 M196.1 M
Slightly volatile
Other Current Assets75.5 M71.9 M15 M
Slightly volatile
Other Stockholder Equity780.5 M743.3 M284.5 M
Slightly volatile
Total Liabilities182.2 M173.5 M65.5 M
Slightly volatile
Property Plant And Equipment Gross60 M57.1 M15.2 M
Slightly volatile
Total Current Assets466.8 M444.6 M180.8 M
Slightly volatile
Common Stock29.5 K31.1 K52.8 K
Very volatile
Short and Long Term Debt Total32.6 M34.7 M19.8 M
Slightly volatile
Short Term Debt4.7 M5 M6.9 M
Slightly volatile
Net Tangible Assets275.6 M262.4 M123.6 M
Slightly volatile
Property Plant Equipment54.3 M51.7 M13.9 M
Slightly volatile
Capital Surpluse695.1 M662 M293.3 M
Slightly volatile
Other Liabilities14 M26.3 M10.8 M
Slightly volatile
Current Deferred Revenue57.2 M54.4 M18.7 M
Slightly volatile
Non Current Liabilities Total83.2 M79.2 M29 M
Slightly volatile
Short and Long Term Debt73.2 M69.8 M18.3 M
Slightly volatile
Net Invested Capital221.7 M320.3 M136.8 M
Slightly volatile
Net Working Capital220.1 M350.3 M140.6 M
Slightly volatile
Long Term Debt49.1 M46.7 M21 M
Slightly volatile
Long Term Debt Total49.1 M46.7 M21 M
Slightly volatile
Capital Stock44.7 K24.3 K132.2 K
Slightly volatile
Capital Lease Obligations18 M34.7 M11.6 M
Slightly volatile
Deferred Long Term Liabilities17.5 M22.9 M16.5 M
Slightly volatile
Non Current Liabilities Other424.9 K447.3 K3.8 M
Slightly volatile

Arcturus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.6 M3.4 M975.6 K
Slightly volatile
Interest Expense530 K882 K482.5 K
Slightly volatile
Selling General Administrative63.8 M60.8 M22.1 M
Slightly volatile
Other Operating Expenses295.8 M281.8 M94.8 M
Slightly volatile
Research Development232 M221 M72.5 M
Slightly volatile
Total Operating Expenses284.9 M271.3 M92.9 M
Slightly volatile
Interest Income14.8 M14.1 M3.2 M
Slightly volatile
Reconciled Depreciation3.3 M3.1 M1.1 M
Slightly volatile
Selling And Marketing Expenses2.4 M2.7 M2.9 M
Slightly volatile

Arcturus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation41.8 M39.8 M12.6 M
Slightly volatile
Begin Period Cash Flow475.7 M453.1 M146.4 M
Slightly volatile
Other Cashflows From Financing Activities4.6 M3.1 M3.9 M
Slightly volatile
Depreciation3.6 M3.4 M961 K
Slightly volatile
End Period Cash Flow421.3 M401.2 M161.1 M
Slightly volatile
Sale Purchase Of Stock1.5 M1.6 M52.3 M
Very volatile
Change To Netincome43.7 M41.6 M13.8 M
Slightly volatile
Cash Flows Other Operating36.2 M34.4 M15.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.554.7920.9229
Very volatile
Days Sales Outstanding44.4466.7744.2939
Slightly volatile
Stock Based Compensation To Revenue0.380.20.4234
Pretty Stable
Capex To Depreciation1.071.132.7643
Slightly volatile
Payables Turnover0.480.53.8369
Slightly volatile
Sales General And Administrative To Revenue0.290.30.9111
Very volatile
Average Inventory0.550.57410.6 K
Slightly volatile
Research And Ddevelopement To Revenue1.041.12.6363
Very volatile
Capex To Revenue0.01570.01660.055
Pretty Stable
Cash Per Share10.049.8711.4603
Pretty Stable
Days Payables Outstanding861749669
Very volatile
Income Quality0.70.550.8289
Pretty Stable
Current Ratio9.315.427.9816
Pretty Stable
Receivables Turnover4.214.4315.8866
Very volatile
Graham Number33.3118.6428.2135
Very volatile
Capex Per Share0.07140.09810.0802
Slightly volatile
Revenue Per Share5.65.333.1351
Slightly volatile
Interest Debt Per Share0.721.050.846
Slightly volatile
Debt To Assets0.07690.08090.7013
Slightly volatile
Days Of Payables Outstanding861749669
Very volatile
Ebt Per Ebit0.390.410.8835
Slightly volatile
Long Term Debt To Capitalization0.260.170.317
Slightly volatile
Total Debt To Capitalization0.110.09791.4396
Slightly volatile
Quick Ratio9.315.427.9857
Pretty Stable
Net Income Per E B T1.091.231.0173
Slightly volatile
Cash Ratio3.123.213.5773
Pretty Stable
Days Of Sales Outstanding44.4466.7744.2939
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.171.331.0797
Pretty Stable
Fixed Asset Turnover4.214.4318.0994
Slightly volatile
Debt Ratio0.07690.08090.7013
Slightly volatile
Price Sales Ratio4.554.7920.9229
Very volatile
Asset Turnover0.20.330.1984
Slightly volatile

Arcturus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap72.5 M118.1 M103.5 M
Slightly volatile
Enterprise Value86.5 M91.6 M78.8 M
Pretty Stable

Arcturus Fundamental Market Drivers

Forward Price Earnings2.4777
Cash And Short Term Investments292 M

Arcturus Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Arcturus Therapeutics Financial Statements

Arcturus Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcturus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcturus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue54.4 M57.2 M
Total Revenue181.4 M190.5 M
Cost Of Revenue3.4 M3.2 M
Stock Based Compensation To Revenue 0.20  0.38 
Sales General And Administrative To Revenue 0.30  0.29 
Research And Ddevelopement To Revenue 1.10  1.04 
Capex To Revenue 0.02  0.02 
Revenue Per Share 5.33  5.60 
Ebit Per Revenue(0.57)(0.60)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Arcturus Stock Analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY